Skip To Main Content
Jayakumar R Nair on Muck Rack

Jayakumar R Nair

As seen in: Nature, MDPI, Science Magazine, The Lancet, Texas Medical Center, The Journal of Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jayakumar R

Contact Jayakumar R, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept study

|
By Tzu-Ting Huang, Elena Giudice, Kristen R. Ibanez, Jayakumar R Nair, Aanika Balaji Warner, Valentina Castañeda Bolaños, Bernadette Redd, Nahoko Sato, Shraddha Rastogi, Sunmin Lee, Alexander Y. Mitrophanov, Stanley Lipkowitz, Kevin Conlon, Chien Huang, Jung-Min Lee, Junya Tabata, Britanny B. Solarz
| Nature Verified
Abstract Here we report the efficacy and translational findings of durvalumab, olaparib, and cediranib (D + O + C) and of durvalumab plus cediranib (D + C) from the recurrent ovarian cancer cohort within a single-center, multi-arm, non-randomized, multi-cohort phase I/II trial (NCT02484404). Sixty-eight patients were enrolled (39 in D + O + C, 29 in D + C). The primary endpoint was objective response rate (ORR); secondary endpoints included progression-free survival (PFS) and safety.
Open in Who Shared Issue with article?

Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant BRCA1-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge

|
By Tzu-Ting Huang, Jayakumar R Nair, Kristen R. Ibanez, Chi-Ting Shih
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

BLM Overexpression as a Predictive Biomarker for CHK1 Inhibitor Response in PARP Inhibitor–Resistant BRCA-Mutant Ovarian Cancer

|
By Nitasha Gupta, Tzu-Ting Huang, Jayakumar R Nair, Daniel An
| Texas Medical Center
Poly(ADP-ribose) polymerase inhibitors (PARPis) have changed the treatment paradigm in breast cancer gene (BRCA)–mutant high-grade serous ovarian carcinoma (HGSC). However, most patients eventually develop resistance to PARPis, highlighting an unmet need for improved therapeutic strategies.
Open in Who Shared Issue with article?
See all 9 articles